iCAD's PrecisionPoint MRI-Guided Interventional Planning Software Receives 510(k) Clearance
Additional capabilities and software updates offer increased diagnostic confidence
Nashua, NH - Apr 16, 2009
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced it has received 510(k) clearance for PrecisionPoint, the company’s interventional planning solution for breast MRI that can make biopsies easier and faster. PrecisionPoint will be offered as an integrated module within the company’s CADvue™ breast MRI image review software.
"We continue to improve upon our software offerings to provide clinicians increasingly accurate tools to aid in the detection of breast cancer. Our new PrecisionPoint software enables the user to pinpoint exactly where the biopsy is needed without the need to manually calculate the location and depth of the lesion,” said Rick Ortega, director of MRI programs at iCAD. “Faster and more reliable biopsies could help reduce the need for repeat exams and aid in quicker clinical decision making and treatment for patients."
In addition to the inclusion of PrecisionPoint, iCAD has made a number of other functional and interface
improvements to the latest release of its CADvue software. CADvue is a complete MRI image review, analysis and
BI-RADS® compatible reporting solution that generates contrast enhancement curves, dynamic 3D images and
quantification of key lesion parameters. CADvue’s automation of critical manual steps reduces the time required to
generate curves and streamlines radiologists’ work flow and diagnosis. The latest CADvue software release includes:
· A compare function that enables radiologists to easily view multiple studies of the same patient;
· Enhancement of MIPs/3D renderings; and
· The addition of CADvue Lite, which gives the user the ability to export CADvue images
onto a CD with a DICOM viewer to support improved communication between physicians.
“The addition of PrecisionPoint, coupled with the new features and product enhancements within
CADvue, gives clinicians a complete set of tools to improve the review and analysis of breast MRI studies,
as well as interventional planning,” said Ortega.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com
For media inquiries, contact Liza Heapes of MS&L
at 617-937-2829 or via e-mail at liza.heapes@mslworldwide.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
"
